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Drug  Discovery,   against  Driver
Mutations(Activating  Mutation)
Effects  and  P roblem s
Drugs against small-molecule substances and antibodies which specif-
ically control genes serving as a driving force for cancer growth, called
activated mutant gene, have been demonstrated to afford the most distinct
beneficial effect among the molecular target drugs currently under inves-
tigation [1]. This is because growth of cancer is dependent solely on the
mutant genes.
These molecular targeted drugs include imatinib directed against break-
point cluster region-abelson (BCR-ABL) for chronic myeloid leukemia
(CML), imatinib directed against mutant c-kit for gastrointestinal stromal
tumor (GIST), erlotinib and gefinitib directed against mutant epidermal
growth factor receptor (EGFR) for non-small cell lung cancer (NSCLC),
crizotinib directed against echinoderm microtubule-associated protein-
like 4-anaplastic lymphoma kinase (EML4-ALK) for NSCLC, and ve-
murafenib directed against mutant B-type Raf kinase (BRAF) for
melanoma. All of these drugs have been demonstrated to yield high re-
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Numerous clinical trials of molecular targeted drugs for cancer have been conducted, with re-
markable results for certain drugs and accumulation of “negative data” causing a hitch in the de-
velopment plan for some other compounds. Five recent issues and problems of molecular targeted
therapies were discussed critically. Drug discovery and effects against driver mutations (activating
mutations) and problems: possibility for circumventing inherent and acquired resistance with the
aim of achieving radical cure. Synthetic lethality: reasonable patient selection in individualized
treatment strategy. Response rate and progression-free survival improvement with or without
overall survival benefit and enhancement of toxicity in bevacizumab therapy: best endpoints for
the evaluation of effect of antiangiogenic therapy. Negative data on small-molecule targeted ther-
apy, primarily vascular endothelial growth factor tyrosine kinase inhibitors: loose GO or NO-GO
decision criteria for further development of new compounds in early clinical trials. Effect of im-
munotherapy: difficulty to verify by proof of principle study. We are faced to many questions for
the development of efficient personalized therapy. Accumulation of scientific global preclinical
and clinical evidences is essential to use these new therapeutic modalities for the improvement
of oncologic health care.
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sponse rates and to significantly prolong the disease-free survival, pro-
gression-free-survival (PFS) and overall survival (OS) when administered
alone, and are hence generally accepted as standard treatments for the rel-
evant disorders  (Table 1) [2,3].
One of the issues needings to be explored is that while a significant
prolongation of OS was demonstrated for imatinib and vemurafenib in
randomized comparative studies with cytotoxic anticancer agents, no such
prolongation of OS has been demonstrated for gefinitib or erlotinib in
spite of their dramatic antitumor activity. Such discrepant results may be
attributable to the molecular target drugs being administered to virtually
all patients in the chemotherapy-treated group in a crossover design after
the disease has progressed. In fact, a comparative study of vemurafenib
versus  dacarbazine  (DTIC)  conducted  in  patients  with  advanced
melanoma using a protocol that prohibited crossover medications demon-
strated a significantly prolonged OS in the vemurafenib-treated group
(Table 2) [4]. This study design was called into question by The New York
Times and other media in the United States from the ethical viewpoint
(Fig. 1) [5]. However, such a study design is perhaps acceptable under
circumstances where it is uncertain whether a drug actually produces a
theoretically anticipated effect or not. In cases for gefinitib and erlotinib,
on the other hand, various clinical trials were conducted at the outset of
the clinical development of these drugs under the assumption that the tar-
get might be wild-type EGFR, and it became evident that patient popula-
tions with such clinical characteristics as adenocarcinomas, non-smokers
and females were likely to benefit to some extent from the targeted ther-
apies. In April and May, 2004, it was reported that the true target of these
drugs was a mutant EGFR [6,7]. Under such a situation, it became ex-
tremely difficult to prohibit a crossover design in comparative studies in
patients bearing mutant EGFR due to ethical reason.
Second problem will be frequency of each driver mutation. BCR-ABL
gene translocation is noted in practically all CML patients. c-kitmutation
in GIST, in which cases imatinib is effective, EGFRmutation in NSCLC,
and BRAFmutation in melanoma are detected in considerable proportion
such as > 90%, about 10-35%, and 40-60%, respectively of the patients
[8-10]. On the other hand, the EML4-ALKfusion gene in NSCLC is found
in only about 4% of patients with adenocarcinoma of the lung [11]. The
frequency of the BRAF mutation in NSCLC is ≤2% [12]. If different
driver mutations were discovered in only small fractions of patients in the
future, individualized drug discovery and selection of patients may pos-
sibly become more and more complicated. Another important problem
to be tackled will be up to what extent of market size contraction the re-
searchers’/firm’s will to discover drugs can be maintained.
Third issue will be circumvention of drug resistance to each drug. These
therapeutic agents produce dramatic effects in most patients at the begin-
ning of the treatment, however, there are some patients who do not re-
spond at all even in the presence of a driver mutation (Resistance 1). It
has been pointed out that this could be attributable to the problem in low
specificity for the detection of mutations. Even among responders, the
majority of patients may fail to achieve complete response, but still show
Table 1. Clinical evidence of oncogene addiction [1]
Target Disease Agent Regimen Response rate (%)
Mutant EGFR NSCLC Gefitinib, erlotinib Monotherapy 70-90
EML4-ALK NSCLC Crizotinib Monotherapy 70-90
BCR/ABL CML Imatinib Monotherapy 70-90
c-KIT GIST Imatinib Monotherapy 45 
Mutant BRAF Melanoma Vemurafenib Monotherapy 50
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; EML4-ALK, echinoderm microtubule-associated protein-like 4-
anaplastic lymphoma kinase; BCR-ABL, breakpoint cluster region-abelson; CML, chronic myeloid leukemia; GIST, gastrointestinal stromal
tumor; BRAF, B-type Raf kinase.
Dacarbazine Vemurafenib
No. of patients 338 337
Response rate (%) 5.5 48.4
Median progression free  1.6 5.3
survival (M)
Hazard ratio, 0.26 (0.20-0.33); p < 0.0001
Overall survival 64 84
(6 mo survival, %)
Hazard ratio, 0.37 (0.26-0.55); p < 0.0001
Table 2. Comparison of overall survival of unresectable BRAF
V600E mutated malignant melanoma treated with dacarbazine vs.
vemurafenib (BRIM3 trial) [4]
Fig. 1. Your Health-CTV Med News Express (From CTV News,
Vemurafenib in melanoma: was its phase 3 trial unethical?, with per-
mission from CTV Television Network) [5].
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partial response (Resistance 2). Furthermore, occurrence of secondary
mutations, such as threonine 790 methionine (T790M) in mutant EGFR,
and emergence of resistance through other mechanisms such as activation
of another signal transduction pathways are also encountered (Resistance
3). Secondary mutations have also been reported in lung cancer with
EML4-ALKfusion gene [13,14].  It is yet to be clarified in regard to Re-
sistance 3, whether the secondary mutation may actually be induced by a
drug or represents the result of selection of a sensitive cell population that
responds to the drug (Table 3). In any event, radical cure cannot be ex-
pected even with sharply acting molecular targeted drugs, unless Resist-
ances 1, 2 and 3 can be circumvented. It is considered an important future
subject of research for clinicians to design appropriate combinations of
molecular targeted drugs and cytotoxic chemotherapy or combinations
of different molecular-targeted drugs. Comparative studies of EGFR-ty-
rosine kinase inhibitor (TKI)±cytotoxic chemotherapy regimens in non-
selected cases of NSCLC have failed to confirm an add-on effect of
EGFR-TKI, however, there is still the hope that improved efficacy might
be obtained with such therapy in EGFRmutation-positive cases by this
strategy. Because median survival time of EGFR-mutation positive pa-
tients improved to 27-30 months after the beginning of treatment by the
sequential combination of EGFR-TKI+cytotoxic drugs. A recent report
described that irreversible EGFR-TKI+cetuximab was effective in EGFR
mutation-positive patients who were no longer responsive to erlotinib or
gefinitib. There is great hope, of course, that drugs capable of circumvent-
ing emergence of resistance will be discovered via elucidation of the un-
derlying mechanisms [15,16].
P atient  S election  in  a  S ynthetic
Lethality  S trategy
Synthetic lethality is a newly-coined term and has been used, for ex-
ample, to explain how poly ADR-ribose polymerase (PARP) inhibitors
are effective only in breast cancer susceptibility gene (BRCA) 1/2muta-
tion-positive cases [17]. PARP plays an important role in repairing sin-
gle-stranded DNA cleavage at the sites of DNA damage caused by
anticancer agents or radiation. Following administration of PARP in-
hibitors, the damaged DNA cannot be repaired, leading to accumulation
of single-stranded DNA breaks which eventually result in double-stranded
DNA breaks. Damaged DNA can be repaired by homologous recombi-
nation in cells with normal BRCA1/2, whereas in BRCA1/2-defective
cells, no such repair of DNA damage is possible, resulting in cellular death
[18-20]. Patients with ovarian cancer or breast cancer with BRCA 1/2mu-
tation/defect have been reported, and clinical studies of profound interest
aimed at synthetic lethality are ongoing (Fig. 2) [18,19,21].
A comparative phase II clinical trial was conducted to assess mainte-
nance therapy with olaparib (PARP inhibitor) in BRCA 1/2mutation-pos-
itive  patients  after  induction  chemotherapy  for  advanced  ovarian
carcinoma. The study population comprised patients who had received
two or more combination chemotherapy regimens including platinum.
Although the study was a phase II trial, the results showed significant pro-
longation of the PFS (p < 0.00001) in patients treated with olaparib as a
maintenance therapy [22]. The results of the phase II study performed in
265 patients with sensitive relapse encouraged to do next phase III study.
Triple-negative breast cancer (TNBC) bears similarity to hereditary
BRCA1/2mutation-positive breast cancer with respect to characteristics
such as the estrogen-receptor/progesterone receptor/human epidermal
1) Wild type tumor
2) Driver mutation positive tumor
(1) Absolutely refratory tumor
PD or SD in spite of driver mutation
(2) Heterogeneity of tumor
Majority achieve only PR
(3) Acquired resistance
Secondary? mutation
Activation of other pathways (T790M)
MET amplification
Activation of HGF mediated pathway
Transformation of pathological characteristics
PD, progressive disease; SD, stabilized disease; PR, partial response;
MET, MNNG HOS transforming gene; HGF, hepatocyte growth
factor.
Table 3. Problems for cure by molecular target therapy
PARP PARP inhibition DNA damage (SSBs)
DNA replication
(accumulation of DNA DSBs)
HR-mediated
DNA repair
Cell survival Cell death
Impaired 
HR-mediated
DNA repair
HR-dificient tumor 
cell (e.g. BRCA 1/2  )
-/-
Normal cell 
with functional HR
 pathway
Tomor-selective cytotoxicity
Fig. 2. Mechanism for synthetic lethality in BRCA1/2 deficient can-
cer. Poly ADR-ribose polymerase (PARP) inhibition produces tumor-
selective synthetic lethaity. When PARP action is inhibited, SS are
converted to DSB at replication. In cells with functional HR pathway,
the DSB will be repaired. In cells with a dysfunctional HR pathway,
as is the case with BRCA 1 and 2, the lesions go unrepaired and cell
death ensues [18,19,21]. BRCA, breast cancer susceptibility gene;
DSB, double-strand break; HR, homologous recombination; SSB,
single-strand break.
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growth factor receptor type 2 (ER/PR/HER2) status, p53 status, mutant-
type gene expression pattern (basal like), histologic type (poorly differ-
entiated), and sensitivity to DNA-damaging anticancer agents (highly
sensitive). Diminished expression of BRCA1/2 is also noted. TNBC has
been recognized to have a distribution which overlaps in part with that of
BRCA1/2mutation (defect)-positive breast cancer.
O’Shaughnessy et al. [23] conducted a comparative phase II study of
gemcitabine+carboplatin±iniparib  in  120  patients  with  TNBC  and 
published the results in the New England Journal of Medicine. The ini-
parib add-on group showed both superior PFS and OS in this phase II
trial (Fig. 3). With the aim of confirming the outcome, a phase III trial was
undertaken in 519 previously treated patients with TNBC, using PFS and
OS as the primary endpoints. The trial seemed a highly hopeful compar-
ative study in which 519 TNBC patients were enrolled within a period of
as short as 9 months from July 2009 to March 2010. The target number
of recruited patients was set at 420 before starting the trial, with hazard
ratios of 0.66 and 0.65 for OS and PFS, respectively, and ʱ-error levels of
0.04 and 0.01, respectively, based on a previous phase II trial which had
demonstrated an add-on effect of the PARP inhibitor. In the phase III study,
however, the hazard ratios for OS and PFS were 0.88 and 0.79, respec-
tively, with p-values of 0.28 and 0.027; hence neither endpoint cleared
the estimated value, yielding negative data [24]. The results were one of
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Fig. 3. Efficacy of iniparib in triple negative breast cancer progression-free survival/overall survival (phase II study). CI, confidence interval [23].
Table 4. Efficacy endpoints for phase III study of iniparib ITT pop-
ulation [24] 
ITT, Intent to treat; GC, gemcitabine-carboplatin; GCI, gemcitabine-
carboplatin plus iniparib; PFS, progression free survival; CI, confi-
dence interval; HR, hazard ratio; OS, overall survival.
Basal-like
subtype
BRCA1-
positive
Triple-negative breast cancer
Fig. 4. Schematic illustration of overlap among triple negative breast
cancer, basal-like, and BRCA1-related tumors adapted from Pal et
al. [25]. BRCA1, breast cancer susceptibility gene.
GC (n=258) GCI (n=261)
PFS (pre-specified alpha=0.01)
Median PFS (95% CI, mo) 4.1 (3.1, 4.6) 5.1 (4.2, 5.8)
HR (95% CI) 0.79 (0.65, 0.98)
p-value 0.027
OS (pre-specified alpha=0.04)
Median OS (95% CI, mo) 11.1 (9.2, 12.1) 11.8 (10.6, 12.9)
HR (95% CI) 0.88 (0.69, 1.12)
p-value 0.28
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the most disappointing among those of clinical studies on molecular tar-
geted drugs reported in 2011 (Table 4) [24]. Most probable explanation
for the disappointing data may be confusion of the concept of BRCA1/2
mutation (defect) with that of BRCA-ness. The background for the study
population consisting of TNBC patients in clinical trials using a PARP in-
hibitor is based on the hypothesis of BRCA-ness that the BRCA1promoter
is methylated or the BRCA1 function is depressed in TNBC. In other
words, mutation/defect of BRCA1/2and BRCA-ness are entirely different
concepts. As can be seen in the Fig. 4, TNBC, basal-like breast cancer
(BC) and BRCA1-mutant or defective BC overlap for a considerable part,
but BRCA1-mutant or defective BC may constitutes a small proportion
of TNBC and basal-like BC [25]. Although, in the phase III trial, clinical
characteristics in PR/ER/HER2-negative cases of TNBC were assessed,
whereas there were no data concerning the BRCA1/2 status, it would be
possible to infer that the proportion of BRCA1/2-mutant (defective) BC
cases in the population enrolled in the phase II and III studies affected the
study results. Thus, effects of the treatment cannot be expected in studies
involving contradiction between the patient inclusion criteria and the target
for the molecular targeted drugs. This suggests the cardinal importance
of appropriate patient selection based on reliable biomarkers.
Response Rate and PFS 
Improvement with/without OS
Prolongation and Enhancement of
Toxicity of Bevacizumab (BEV)
Therapy
Angiogenesis inhibitors have been evaluated in clinical studies on a
variety of malignancies because they are considered to be non-organ-spe-
cific from the viewpoint of efficacy, in as much as angiogenesis inhibitors
exert their effects on the cancer milieu rather than on the cancer cells per
se. Biomarkers to estimate therapeutic responses, if present at all, cannot
be used for a qualitative estimation of the responses to angiogenesis in-
hibitors in terms of a ‘yes’ or ‘no.’ Several comparative studies of BEV
have been conducted, which have generated data indicating that while the
response rate and PFS improved, there was still no significant improve-
ment of the OS following BEV therapy combined with chemotherapy in
most instances (Tables 5 and 6) [26]. Prolongation of OS occurred only
in colorectal cancer, following use of BEV in combination with irinote-
Table 5. Clinical benefit with bevacizumab (BV) in phase III studies: part 1
Primary site Regimen Publication  RR PFS OS
M-BC (R) Capecitabine±BV JCO 2005 [27] Ⓥￗￗ
M-BC (E2100) Paclitaxel±BV NEJM 2007 [28] ⓋⓋￗ
M-BC (AVADO) Docetaxel±BV JCO 2010 [29] ⓋⓋￗ
M-BC (RIBBON) Anthra/Toxan/Cape±BV JCO 2011 [30] NE Ⓥￗ
M-CRC IFL±BV NEJM 2005 [31] NE ⓋⓋ
M-CRC (R) FOLFOX±BV JCO 2005 [32] NE NE Ⓥ
M-CRC XELOX/FOLFOX±BV JCO 2008 [33] NE Ⓥￗ
Adjuvant (RC) FOLFOX6±BV JCO 2009 [34] NE ￗ NE
RR, relative risk; PFS, progression-free survival; OS, overall survival; JCO, Journal of Clinical Oncology; NEJM, New England Journal of Med-
icine; IFL, irinotecan/fluorouracil/leucovorin; FOLFOX, oxaliplatin/fluorouracil/leucovorin; Ⓥ, significant; ￗ, not significant; NE, not evaluable.
Table 6. Clinical benefit with bevacizumab (BV) in phase III studies: part 2
Primary site Regimen Publication RR PFS OS
M-NSCLC CBDCA+TXL±BV NEJM 2006 [35] ⓋⓋⓋ
M-NSCLC CDDP+GEM±BV JCO 2009 [36] ⓋⓋￗ
Renal cell (AVOREN) IFN±BV Lancet 2007 [37] NE Ⓥￗ
Gastric ca (AVAGAST) Cap/FU+CDDP±BV JCO 2011 [38] ⓋⓋￗ
Ovarian ca (GOG-0218) CBDCA+TXL±BV JCO 2010 [39] NE Ⓥￗ
Ovarian ca (ICON7) CBDCA+TXL±BV JCO 2011 [40] --- Ⓥￗ
Ovarian ca (OCEANS) CBDCA+GEM±BV JCO 2011 [41] ⓋⓋￗ
RR, response rate; PFS, progression-free survival; OS, overall survival; NSCLC, non-small cell lung cancer; CBDCA, carboplatin; TXL, paclitaxel;
NEJM, New England Journal of Medicine; CDDP, cisplatin; GEM, gemcitabine; JCO, Journal of Clinical Oncology; Ca, cancer; AVOREN, Phase
III trial of bevacizumab plus interfern alfa-2a in patients with metastatic renal cell carcinoma; IFN, interferon; NE, not evaluable; AVAGAST, a
randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with
advanced gastric cancer; GOG, Gynecologic Oncology Group; ICON, a randomized, two arm, multicenter Gynecologic Cancer InterGroup trial
of adding bevacizumab to standard chemotherapy; OCEANS, a randomized, double blinded, placebo-controlled, phase III trial of chemotherapy
with or without bevacizumab in patients with platinum sensitive recurrent epithelial ovarian, primary peritoneal or fallopian, tube cancer; Ⓥ, sig-
nificant; ￗ, not significant.
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can/fluorouracil/leucovorin or oxaliplatin/fluorouracil/leucovorin (FOL-
FOX) therapy and paclitaxel+carboplatin regimens for non-small cell car-
cinoma. In all studies including E2100 [28,42], BEV and Docetaxel
(AVADO) [29] and Regimens in Bevacizumab for Breast Oncology
(RIBBON) [30,43] trials conducted in patients with advanced BC, only
the response rate and PFS improved, with no significant prolongation of
the OS, therefore, cancellation of the accelerated approval on the basis of
the E2100 trial data has been decided in United States Food and Drug
Administration (US FDA) based on Oncology Drug Advisory Committee
(ODAC) recommendation (Table 7). Similar results were obtained in the
Gynecologic Oncology Group (GOG) 0218 [39], a randomized, double
blinded, placebo-controlled, Phase III trial of chemotherapy with or with-
out bevacizumab in patients with platinum sensitive recurrent epithelial
ovarian, primary peritoneal or fallopian, tube cancer (OCEANS) [41] and
a randomized, two arm, multicenter Gynecologic Cancer InterGroup trial
of adding bevacizumab to standard chemotherapy (ICON7) [40] studies
conducted in patients with ovarian cancer. A comparative phase II trial
was performed in lung cancer in Japan using the same schedule as that in
the E4599 study and this trial failed to demonstrate any significant im-
provement of the OS in the BEV treatment group. Possible reasons for
these failures may include 1) the problem of bias in evaluating the PFS,
namely, the PFS in the BEV-treated group merely appeared to be better
at a glance due to observation bias; 2) an insufficient degree of improve-
ment for antitumor effect of the chemotherapy prescribed concomitantly
with BEV; and 3) alterations of the biological characteristics of the residual
tumor after combined treatment with BEV-chemotherapy, which may
cause the malignant cancer cells to survive and proliferate rapidly in spite
of continued treatment. Issues that need to be investigated in relation to
the use of BEV may include 1) validity of continued use of BEV even
after completion of chemotherapy in combined treatment with chemother-
apy; 2) non-negligible adverse reactions that are observed even after ex-
clusion of high-risk patients; 3) high drug prices (Fig. 5); and 4) limited
degree of efficacy.  BEV is prescribed in only about 10 to 20% of patients,
even in the United States, where it is approved for use in the treatment of
non-small-cell carcinoma of the lung, therefore, the propriety of the use
of BEV should be judged after sufficient analysis of various factors.
6,000
4,000
2,000
U
S
$
CBDCA+PTL CBDCA+PTL+Bev
CBDCA
PTL
Bev
Fig. 5. Increased treatment cost by bevacizumab (Bev). CBDCA,
carboplatin; PTL, paclitaxel.
Table 7. Voting results of ODAC for bevacizumab in breast cancer
Question Results of ODAC (6 members）
ODAC, Oncology Drug Advisory Committee; AVADO, bevacizumab plus docetaxel in metastatic breast cancer; RIBBON, randomized, double-
blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first line treatment of HER2-negative locally recurrent
or metastatic breast cancer; FDA, Food and Drug Administration; GNE, Genetec Co.
Issue 1
Issue 2A
Issue 2B
Issue 3
Do the AVADO and RIBBON1 trials fail to verify the clinical benefit of Avastin for the
breast cancer indication for which it was approved?
Yes: agree for FDA, No: agree for GNE
Does the available evidence on Avastin demonstrate that the drug has not been shown to
be effective for the breast cancer indication for which it was approved?
Yes: agree for FDA，No: agree for GNE
Does the available evidence on Avastin demonstrate that the drug has not been shown to
be safe for the breast cancer indication for which it was approved, in that Avastin has not
been shown to present a clinical benefit that justifies the risks associated with use of the
product for this indication?
Yes: agree for FDA，No: agree for GNE
If the Commissioner agrees with the grounds for withdrawal set out in issue 1, issue 2.A,
or issue 2.B, should FDA nevertheless continue the approval of the breast cancer indica-
tion while the sponsor designs and conducts additional studies intended to verify the
drug’s clinical benefit?
Yes: agree for GNE，No: agree for FDA
Yes (agree for FDA): 6
No (agree for GNE): 0
Yes (agree for FDA): 6
No (agree for GNE): 0
Yes (agree for FDA): 6
No (agree for GNE): 0
Yes (agree for GNE): 0
No (agree for FDA): 6
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Accumulating Negative Data on
Small-Molecule Kinase 
Inhibitors: Loose GO or NO-GO
Decision Criteria on Further 
Development of New Compounds
Numerous studies for the development of small-molecule kinase
(SMK) inhibitors are currently in progress. Among the most prominent
SMK inhibitors that are under development are the multitargeted kinase
inhibitors, targeting mainly on vascular endothelial growth factor receptor.
Such multitargeted SMK inhibitors as sunitinib and sorafenib have been
already in the market and are used as therapeutic agents renal cancer and
hepatoma, but the precise mechanism of antitumor effect of these drugs
remains unclear. The results of many clinical studies on SMK inhibitors
under development have yielded negative data. The reason thereof may
be said to be a mistake based on loose criteria for the GO or NO-GO de-
cision about proceeding from non-clinical studies to clinical trials and
from early-phase clinical trials to phase III trials [26]. It seems often the
case that the magnitude of the antitumor effect is misjudged for data of
non clinical studies. The non-clinical study data which have come to our
notice are largely favorable and purport to demonstrate theoretically ten-
able antitumor effects. We must not disregard the possibility that there ac-
tually exists a vast amount of negative data underneath of positive results.
On the other hand, insufficiently explained positive data also exist, and in
some cases, an effect on a target distinct from an initially anticipated target
is ultimately linked with the observed therapeutic effect. Designs of early
phase clinical trials and interpretation of proof of principle (POP) data
also have great influence on the GO/NO-GO decision preceding a big
scale phase III trial. It is also an important subject as to which of the hith-
erto obtained study data recognized as global standards can be considered
as reliable. Gefitinib and erlotinib are thought to be first-line drugs for the
treatment of non-small-cell carcinoma expressing EGFRmutations; how-
ever, strangely, patient selection is generally considered unnecessary while
prescribing erlotinib, as second-line treatment. Erlotinib has been strangely
believed to be active even for patients without EGFRmutation in western
investigators based on the results of BR-21 study [44]. On the other hand,
gefitinib is considered to be inactive based on the results of IRESSAPan
Asia Study (IPASS) trial [45] in n spite of the statistical demonstration for
non- inferiority of gefitinib in Gefitinib and docetaxel trial in previously
treated non-small cell lung cancer (INTEREST) study [46]. It would also
be a future important subject to explore the validity of assessing the add-
on effect of a new SMK inhibitor in a phase III comparative study of sec-
ond-line and third-line regimens using erlotinib [47] in a comparator group
in non-selected patients with non-small-cell carcinoma. It can be readily
assumed that a comparative study of a multitargeted SMK inhibitor with
or without a concomitant merely cytotoxic anticancer agent with the an-
ticancer agent alone will yield negative data if tumor shrinkage may not
be expected from monotherapy with the multitargeted SMK inhibitor di-
rected towards mutations other than the driver mutation. This is simply
because add-on effect can hardly be expected from a compound with only
a small degree of antitumor effect.
Effect of Immunotherapy 
nearly Impossible to Verify by 
a POP Study
Immunotherapy was once regarded as a dubious treatment. Although
the underlying mechanism of action can be cogently described, it is too
complex and nearly impossible to verify through POP studies. There is
no other means than demonstrating an overwhelming therapeutic effect
of immunotherapy in scientific clinical studies to convince researchers,
regulatory authorities and patients, in particular, under such circumstances.
Recently, positive data on immunotherapy have been reported sporadi-
cally seen in the literature. Manufacture of Sipuleucel-T has been ap-
proved by the US FDA. Sipuleucel-T is a treatment consisting of injection
of autologous peripheral blood dendritic cells, cultured in the presence of
PA2024, a fusion protein composed of prostatic acid phosphatase (PAP)
linked to granulocyte-macrophage colony-stimulating factor, which is an
activated immune cell preparation targeted against PAP antigen. This com-
plicated therapy was evaluated in a randomized placebo-controlled dou-
ble-blind trial in 1,512 patients with asymptomatic, metastasis-positive,
non-androgen-dependent cancer of the prostate (IMPACT Study). The
mean survival time was 25.8 months in the Sipuleucel-T therapy group,
as compared to 21.7 months in the placebo group (p=0.017); hence, the
outcome was superior in the former [48], and the therapy was approved
by the FDA on April 29, 2010, based on these results. This is a first ap-
proval of immunotherapy in US FDA.
At the 2010 American Society of Clinical Oncology (ASCO) Annual
Meeting, a three-group parallel trial of the following three treatment
groups,  namely,  ipilimumab+gp100,  ipilimumab+placebo  and
gp100+placebo, in previously treated patients with malignant melanoma
(molecular diagnostics [MDX] 010-20 Study) was reported. Gp100 anti-
gen is expressed in the majority of melanoma cells. It has been reported
that the cytotoxic T-lymphocyte antigen (CTLA)-4 on T cells inhibits
binding of cluster of differentiation 28 (CD28) to B7 on the T cells by
CTLA-4
CTLA-4
CTLA-4
T cell T cell T cell
TCR TCR TCR
MHC MHC MHC
APC APC APC
CD28 CD28
B7 B7 B7
T-cell
activation
IPLIMUMAB
blocks
CTLA-4
T-cell
inhibition
T-cell
potentiation
Fig. 6. Mode of action of ipilimumab. CTLA-4, cytotoxic T-lym-
phocyte antigen-4; TCR, T-cell receptor; MHC, major histocompat-
ibility complex; APC, antigen-presenting cell.
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Table 8. Comparison of monotherapy with ipilimumab or GP100 peptide vaccine and the combination in patients with previously treated unre-
sectable stage III or IV melanoma: Study MDX010-20 [38]
No. of patients No. of death Response rate (%)
Median OS Hazard ratio
p-value
(95% CI, mo) (95% CI)
Ipilimumab+gp 100 403 306 5.7 10.0 (8.5-11.5)
0.68 (0.55-0.8) 0.00004
Placebo+gp 100 136 119 1.5 6.4 (5.5-8.7)
0.66 (0.51-0.87) 0.0026
Ipilimumab+placebo 137 100 10.9 10.1 (8.0-13.8)
OS, overall survival; CI, confidence interval.
Table 9. Comparison of ipilimumab (IPI) plus dacarbazine (DTIC) vs. DTIC alone as first line treatment in patients with unresectable stage III
or IV melanoma [39]
IPI+ DTIC  DTIC alone p-value
No. of patients 250 252
Response (CR+PR) (%) 38 (15.2) 26 (10.3)
Duration of response (mo) 9.3 8.1
Overall survival HR (95% CI) 0.72 (0.59-0.87)
0.0009
Median (mo) 11.2 9.1
Progression free survival HR (95% CI) 0.76 (0.63-0.93)
0.006
Median (mo) 2.8 2.6
CR, complete response; PR, partial response; HR, harzard ratio; CI, confidence interval.
binding B7 on antigen presentation cells, thereby suppressing T cell acti-
vation (Fig. 6). It has been speculated that the binding of CD28 to B7 be-
comes possible when CTLA-4 is blocked by ipilimumab, resulting in T
cell activation, and its function becomes enhanced. In the MDX010-20
Study with the primary endpoint consisting of assessments of the pro-
longing effects for OS of the ipilimumab+gp100 group (Arm A) and
gp100 (Arm C) as the positive control group, the study was designed to
also enable comparison of the gp100 group and an ipilimumab group
(Arm B) (Table 8). Results of the study showed that the results in Arms A
and B were significantly superior in terms of the OS than in Arm C. There
was no significant difference between Arms A and B in the OS, although
it was a little bit better in Arm B [49]. At the 2011 ASCO Annual Meeting,
a randomized comparative trial to evaluate the add-on effect of ipilimumab
to dacarbazine (DTIC), which is the standard treatment for previously un-
treated melanoma was reported. The combined therapy of ipilimumab
and DTIC group showed superior OS (hazard ratio, 0.72; p=0.0009), PFS
and duration of sustained response (Table 9) [50]. It seems very likely that
this  combination  therapy  will  become  the  standard  treatment  for
melanomas, and studies may probably generate results of various assess-
ments of this treatment as adjuvant therapy.
Ipilimumab is an antibody to CTLA-4 and works by restoring T cell
activity. It has the effect of indirectly potentiating immunity, yet the effect
is non-specific. It is considered an important problem to deal with how
POP studies should be conducted in the case of such a compound. Rapid
improvement of therapeutic responses using combined vemurafenib plus
ipilimumab therapy for BRAF V600E mutation positive melanoma is ex-
pected.
Conclusion
Five topics pertaining to the effects and problems of the currently avail-
able molecular targeted therapies for malignancies have been reviewed
critically. Personalized cancer therapy using molecular targeted drugs have
just integrated in clinical practice, however, majority of cancer patients
still cannot be cured. Beside, molecular targeted therapies show more than
minimal problems including patient selection, drug induced adverse
events and high costs. Physicians should make an effort to be fully aware
of these problems and to devote for research and medical practice to im-
prove oncologic medical care.
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